AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01928862
Drug: Prepopik® 1 Sachet x 2 (13-16 years)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03272477
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
Trial: NCT01360658
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of 2 g/kg intravenous immunoglobulins over 2 days
Trial: NCT00983268
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg taken by mouth on the days of radiation only.
Trial: NCT02882555
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
Trial: NCT02581696
Drug: Lafutidine
RxNorm normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lafutidine 10mg, 1 tablet, bid
Trial: NCT01463371
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg three times a week during three months
Trial: NCT00634088
Drug: Ixabepilone + Lapatinib + Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
Trial: NCT02290821
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02290821
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00647127
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl: 25microg/h
Trial: NCT00647127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
Trial: NCT02592746
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
Trial: NCT02244307
Drug: alpha-adrenergic blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03626012
Drug: BIIB078
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT03626012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT02483858
Drug: PQR 309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
Trial: NCT03248167
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be administered to 48 individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 48 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (600 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
Trial: NCT01970241
Drug: NPH
RxNorm normalized name: ZENPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH given per study table based on steroid dose and patient weight in kg.
Trial: NCT01970241
Drug: Correction Factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
Trial: NCT02388464
Drug: MTP-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTP-131 (low dose) administered as single intravenous infusion over 4 hours
Trial: NCT02388464
Drug: MTP-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
Trial: NCT02388464
Drug: MTP-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTP-131 (high dose) administered as single intravenous infusion over 4 hours
Trial: NCT02388464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
Trial: NCT00615693
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02595866
Drug: Antiretroviral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00319202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration for 6 months
Trial: NCT00310336
Drug: S-adenosyl-L-methionine
RxNorm normalized name: S-Adenosyl-L-Methionine (Sam-E)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01331746
Drug: APD515
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oromucosal-oral administration qds for 7 days
Trial: NCT01331746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qds for 7 days
Trial: NCT03835481
Drug: Placebo to match BI 730357
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT03640507
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
Trial: NCT00191945
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00392587
Drug: GW856553
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04416334
Drug: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
Trial: NCT01608737
Drug: PegIFN/RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN/RBV for 48 weeks
Trial: NCT00829881
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single placebo capsule
Trial: NCT01018017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
Trial: NCT01018017
Drug: SRT2104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
Trial: NCT01014936
Drug: MSC2156119J
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00481195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
Trial: NCT03344042
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mcg Fentanyl
Trial: NCT03344042
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mcg sufentanil
Trial: NCT02876900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will evaluate placebo transdermal patch.
Trial: NCT03999411
Drug: Nicoderm C-Q Transdermal Product
RxNorm normalized name: Nicoderm C-Q Transdermal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)
Trial: NCT03850873
Drug: TQB3616
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily
Trial: NCT00909779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation solution, twice daily (BID) for a duration of one year.
Trial: NCT03710655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of 0.01 microliters
Trial: NCT00649896
Drug: Mylan Estradiol Transdermal System 0.025 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00649896
Drug: Climara® Transdermal System 0.025 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01743287
Drug: Imotun capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks
Trial: NCT01743287
Drug: Imotun capsule placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imotun capsule placebo: per oral, a capsule a day during 24 weeks
Trial: NCT02738333
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally once daily
Trial: NCT02738333
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg tablet administered orally once daily
Trial: NCT02009631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04174287
Drug: F-18-AV45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will enroll 200 patients with prodromal AD and mild AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
Trial: NCT01098188
Drug: LFB-R603
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration, dose-escalation study
Trial: NCT02971202
Drug: Hyperinsulinemic, euglycemic clamp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~* insulin (12 mU/m\^2/min \[3x basal\] for 150 minutes, then 40 mU/m\^2/min \[10x basal\] for 180 minutes)~* glucagon (0.65 ng/kg/min \[1x basal\] for 330 minutes)~* somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.
Trial: NCT02971202
Drug: 20% dextrose
RxNorm normalized name: Aminosyn II 4.25% in 20% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.
Trial: NCT01631487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple (once daily for 21 days) oral doses of matching placebo.
Trial: NCT01018173
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc weekly
Trial: NCT00009880
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04135846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02953808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
Trial: NCT02738541
Drug: PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
Trial: NCT00389376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00389376
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mg every 8 hours
Trial: NCT00389376
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 280 mg single dose
Trial: NCT00389376
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 280 mg single dose + every 8 hours
Trial: NCT00389376
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 560 mg single dose + every 8 hours
Trial: NCT00790439
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anticoagulant
Trial: NCT02668588
Drug: extended release of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 intramuscular injection of extended release of placebo
Trial: NCT00389376
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 280 mg every 8 hours
Trial: NCT00389376
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 mg single dose + every 8 hours
Trial: NCT06094244
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Doses of rosuvastatin of up to 10 mg/d.
Trial: NCT01141998
Drug: Calcium, Dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.
Trial: NCT01059864
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
Trial: NCT03815448
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.
Trial: NCT02953808
Drug: GSK2315698
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
Trial: NCT02846207
Drug: Yiqi huoxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
Trial: NCT02846207
Drug: Yiqi group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus 60g.Oral administration, twice one day, for 12weeks.
Trial: NCT00479128
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose: 12.5 mg/m\^2 IV Over 15-30 minutes
Trial: NCT01120470
Drug: OGX-427
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV
Trial: NCT02617407
Drug: Livionex® Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral application Dental Plaque, Gingivitis and Oral Microbiome Control.
Trial: NCT02617407
Drug: PreviDent 5000 plus/Tom's of Maine Children's toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral application for Dental Plaque, Gingivitis and Oral Microbiome Control.
Trial: NCT02836470
Drug: LB1148
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 700 mL of drug product will be administered orally as a split dose before surgery.
Trial: NCT02836470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 700 mL of placebo will be administered orally as a split dose before surgery.
Trial: NCT02846207
Drug: Huoxue group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
Trial: NCT02846207
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrin,oral administration, twice one day, for 12weeks.
Trial: NCT01373008
Drug: Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
Trial: NCT01541735
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 40 mg dose.
Trial: NCT00934739
Drug: Cyclophosphamide, Dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
Trial: NCT00069875
Drug: LY293111
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01445535
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given with siplizumab and etoposide, prednisone, vincristine, doxorubicin and rituximab every 21 days
Trial: NCT01445535
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be given with siplizumab and etoposide, prednisone, cyclophosphamide and rituximab every 21 days
Trial: NCT02383888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03367962
Drug: [18F]F-Ara-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the \[18F\]F-AraG tracer will be administered as a single bolus injection of approximately 5 mCi into a hand or arm vein.
Trial: NCT02494973
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.
Trial: NCT02494973
Drug: LV5FU2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
Trial: NCT00418600
Drug: Hectorol® (doxercalciferol capsules)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hectorol capsules at 1.0 times current injection dose
Trial: NCT03051880
Drug: Repair Control EGF®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)
Trial: NCT03051880
Drug: Cream without rhEGF
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF
Trial: NCT03362281
Drug: amoxicillin and clarithromycin
RxNorm normalized name: omeprazole, amoxicillin and clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
Trial: NCT01297608
Drug: caoted suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: coated suppository with active drug
Trial: NCT01297608
Drug: coated suppository
RxNorm normalized name: Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: coated suppository with placebo
Trial: NCT00463749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl as placebo
Trial: NCT00929682
Drug: Randomization between two referenced treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1.